Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
University Of Montréal currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active matter is assigned to 1 distinct art unit, showing a specific technical focus for the current prosecution efforts. The examination is being conducted by a distinct examiner, which limits the current administrative interactions to a single point of contact at the USPTO.
The busiest examiner for this portfolio is OH, TAYLOR V, who is responsible for the 1 pending office action. Since there is only a single pending action in the entire portfolio, this examiner handles the total current workload for University Of Montréal. Practitioners can focus their strategy entirely on the specific requirements and historical patterns of this individual and the art unit involved.
The alignment of the pending office action with a distinct examiner and art unit suggests a streamlined path for the current application. In the Biotechnology & Pharmaceuticals sector, such focused prosecution allows for a direct dialogue with OH, TAYLOR V. Success in this matter will depend on addressing the specific concerns raised in the single pending action without the complexity of managing multiple examiners or art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OH, TAYLOR V | 1 | 81.3% | +15.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18779877 | ANTICHOLINERGIC COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | OH, TAYLOR V | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18779877 | ANTICHOLINERGIC COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | OH, TAYLOR V | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18779877 | ANTICHOLINERGIC COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | OH, TAYLOR V | 1625 | §102§112 | Non-Final OA | — | Pending | Jul 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity Of Montréal has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Taylor V Oh has the most, with 1 of University Of Montréal's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
